Generate Biomedicines has completed its IPO, raising an impressive $400 million that makes it the largest listing for a biotech on the Nasdaq so far this year. Incubated by investment group Flagship ...
Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...
Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...
Discover 8 best online JavaScript compilers to practice code instantly. Compare features, speed, and ease of use. Start coding today!
Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 million in an initial public offering, as listing activity in ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Somerville company aims to ...
Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...
Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...
I'm an independent creator passionate about building useful tools, simulations, and theories that make complex ideas more accessible. I explore the intersection of technology, education, and human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results